Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 27 Parkinson Disease 4, Autosomal Dominant Lewy Body 24 Neoplasms 14 Melanoma 9 Endometrial Neoplasms 8 Carcinoma, Renal Cell 7 Carcinoma, Non-Small-Cell Lung 7 Thyroid Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Cholangiocarcinoma 6 Stomach Neoplasms 4 Recurrence 4 Carcinoma 4 Biliary Tract Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Lymphoma 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Paraganglioma, Extra-Adrenal 2 Osteosarcoma 2 Neuroendocrine Tumors 2 Lung Neoplasms 2 Liver Neoplasms 2 Glioma 2 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid cancer, Hurthle cell 1

Interventions

Doxorubicin 13 Gemcitabine 10 Ifosfamide 9 Trabectedin 7 Radiotherapy 7 Docetaxel 5 Dacarbazine 5 pazopanib 3 Sunitinib 3 Sorafenib 3 Nivolumab 3 Filgrastim 3 pembrolizumab 2 pegfilgrastim 2 liposomal doxorubicin 2 eribulin 2 cixutumumab 2 belinostat 2 Radiotherapy, Conformal 2 Imatinib Mesylate 2 Chemotherapy, Adjuvant 2 Bevacizumab 2 tremelimumab 1 temsirolimus 1 soblidotin 1 selinexor 1 sargramostim 1 saracatinib 1 rubitecan 1 romidepsin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Leiomyosarcoma × lenvatinib × Clear all

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡